136 related articles for article (PubMed ID: 34118691)
1. Anti-tumor effects of rigosertib in high-risk neuroblastoma.
Radke K; Hansson K; Sjölund J; Wolska M; Karlsson J; Esfandyari J; Pietras K; Aaltonen K; Gisselsson D; Bexell D
Transl Oncol; 2021 Aug; 14(8):101149. PubMed ID: 34118691
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma.
Hansson K; Radke K; Aaltonen K; Saarela J; Mañas A; Sjölund J; Smith EM; Pietras K; Påhlman S; Wennerberg K; Gisselsson D; Bexell D
Sci Transl Med; 2020 Sep; 12(562):. PubMed ID: 32967973
[TBL] [Abstract][Full Text] [Related]
3. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
[TBL] [Abstract][Full Text] [Related]
5. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
6. Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.
Taylor JS; Yavuz B; Zeki J; Wood L; Ikegaki N; Coburn J; Harrington K; Shimada H; Kaplan DL; Chiu B
Surgery; 2020 Jun; 167(6):969-977. PubMed ID: 32122657
[TBL] [Abstract][Full Text] [Related]
7. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
8. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
[TBL] [Abstract][Full Text] [Related]
10. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
11. [Anti-Tumor Effect of Rigosertib on HEL and K562 Cells and Its Related Mechanism].
Xu F; Chang CK; Li X; He Q; Wu LY; Zhang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1362-1366. PubMed ID: 29070108
[TBL] [Abstract][Full Text] [Related]
12. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
[TBL] [Abstract][Full Text] [Related]
14. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
[TBL] [Abstract][Full Text] [Related]
15. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells.
Clark RA; Lee S; Qiao J; Chung DH
Oncotarget; 2020 Aug; 11(32):3069-3077. PubMed ID: 32850011
[TBL] [Abstract][Full Text] [Related]
17. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
18. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
20. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
